The erosion of traditional insulin tracking forces biowearables to pivot toward multi-analyte metabolic companionship.
To defend against the risk of GLP-1 drugs rendering standard continuous glucose monitors obsolete, manufacturers are bundling behavioral coaching and testing secondary biomarkers like ketones and potassium.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Device manufacturers are shifting toward multi-analyte metabolic companionship as core insulin tracking becomes commoditized.
Faced with GLP-1-driven changes in insulin demand, device makers are actively pivoting to multi-analyte systems targeting metabolic wellness.
The shift in Dexcom's pipeline toward cardiorenal biomarkers highlights how device manufacturers are adapting to support patients beyond simple blood glucose tracking.